2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
3
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
CNS
6
Sarcoma
3
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Brain Neoplasms
2
Recurrence
1
Glioma
1
Interventions
Radiotherapy
221
Cyclophosphamide
211
Doxorubicin
210
Temozolomide
182
Ifosfamide
121
Filgrastim
111
Imatinib Mesylate
104
Etoposide
101
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
81
Irinotecan
79
pembrolizumab
75
Radiation
70
Carboplatin
65
Methotrexate
62
pazopanib
61
Nivolumab
58
Cisplatin
58
fludarabine phosphate
57
Surgical Procedures, Operative
57
Peripheral Blood Stem Cell Transplantation
57
Specimen Handling
56
Trabectedin
52
Docetaxel
50
Biopsy
50
Busulfan
49
Melphalan
46
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
rindopepimut
×
Sarcoma
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled
NCT00626015
2016-01-21
ZAP IT
Duke University
Phase 1
Completed
16 enrolled